- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 214864, 10 pages
Expression of Syndecan-4 and Correlation with Metastatic Potential in Testicular Germ Cell Tumours
1Hematology Division, Department of Internal Medicine, University Hospital of Patras, 26500 Patras, Greece
2Clinical Oncology Laboratory, Division of Oncology, Department of Medicine, University Hospital of Patras, 26500 Patras, Greece
3Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece
4Department of Pathology, University Hospital of Patras, 26500 Patras, Greece
5Division of Urology, Department of Medicine, University Hospital of Patras, 26500 Patras, Greece
Received 30 April 2013; Accepted 28 May 2013
Academic Editor: Martin Götte
Copyright © 2013 Vassiliki T. Labropoulou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- X. Peng, X. Zeng, S. Peng, D. Deng, and J. Zhang, “The association risk of male subfertility and testicular cancer: a systematic review,” PloS ONE, vol. 4, no. 5, Article ID e5591, 2009.
- D. J. Vidrine, J. E. H. M. Hoekstra-Weebers, H. J. Hoekstra, M. A. Tuinman, S. Marani, and E. R. Gritz, “The effects of testicular cancer treatment on health-related quality of life,” Urology, vol. 75, no. 3, pp. 636–641, 2010.
- A. Diéz-Torre, U. Silván, O. De Wever, E. Bruyneel, M. Mareel, and J. Aréchaga, “Germinal tumor invasion and the role of the testicular stroma,” International Journal of Developmental Biology, vol. 48, no. 5-6, pp. 545–557, 2004.
- A. Heidenreich, I. A. Sesterhenn, F. K. Mostofi, and J. W. Moul, “Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis,” Cancer, vol. 83, no. 5, pp. 1002–1011, 1998.
- D. C. Gilbert, I. Chandler, B. Summersgill et al., “Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours,” International Journal of Andrology, vol. 34, no. 4, pp. e114–e121, 2011.
- E. Milia-Argeiti, E. Huet, V. T. Labropoulou, et al., “Imbalance of MMP-2 and MMP-9 expression versus TIMP-1 and TIMP-2 reflects increased invasiveness of human testicular germ cell tumours,” International Journal of Andrology, vol. 35, no. 6, pp. 835–844, 2012.
- A. D. Theocharis, D. H. Vynios, N. Papageorgakopoulou, S. S. Skandalis, and D. A. Theocharis, “Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma,” International Journal of Biochemistry and Cell Biology, vol. 35, no. 3, pp. 376–390, 2003.
- S. S. Skandalis, V. T. Labropoulou, P. Ravazoula et al., “Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas,” BMC Cancer, vol. 11, article 314, 2011.
- A. D. Theocharis, “Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin,” Biochimica et Biophysica Acta, vol. 1588, no. 2, pp. 165–172, 2002.
- J. Tímár, K. Lapis, J. Dudás, A. Sebestyén, L. Kopper, and I. Kovalszky, “Proteoglycans and tumor progression: janus-faced molecules with contradictory functions in cancer,” Seminars in Cancer Biology, vol. 12, no. 3, pp. 173–186, 2002.
- A. D. Theocharis, S. S. Skandalis, G. N. Tzanakakis, and N. K. Karamanos, “Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting,” FEBS Journal, vol. 277, no. 19, pp. 3904–3923, 2010.
- V. T. Labropoulou, A. D. Theocharis, P. Ravazoula et al., “Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours,” Histopathology, vol. 49, no. 6, pp. 582–593, 2006.
- J. R. Couchman, “Transmembrane signaling proteoglycans,” Annual Review of Cell and Developmental Biology, vol. 26, pp. 89–114, 2010.
- D. M. Beauvais and A. C. Rapraeger, “Syndecan-1-mediated cell spreading requires signaling by αvβ3 integrins in human breast carcinoma cells,” Experimental Cell Research, vol. 286, no. 2, pp. 219–232, 2003.
- S. Clasper, S. Vekemans, M. Fiore et al., “Inducible expression of the cell surface heparan sulfate proteoglycan syndecan-2 (fibroglycan) on human activated macrophages can regulate fibroblast growth factor action,” Journal of Biological Chemistry, vol. 274, no. 34, pp. 24113–24123, 1999.
- C. Mundhenke, K. Meyer, S. Drew, and A. Friedl, “Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas,” American Journal of Pathology, vol. 160, no. 1, pp. 185–194, 2002.
- M. P. O'Connell, J. L. Fiori, E. K. Kershner et al., “Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells,” Journal of Biological Chemistry, vol. 284, no. 42, pp. 28704–28712, 2009.
- L. Carvallo, R. Muñoz, F. Bustos et al., “Non-canonical Wnt signaling induces ubiquitination and degradation of Syndecan4,” Journal of Biological Chemistry, vol. 285, no. 38, pp. 29546–29555, 2010.
- S. Brule, V. Friand, A. Sutton, F. Baleux, L. Gattegno, and N. Charnaux, “Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells,” Biochimica et Biophysica Acta, vol. 1790, no. 12, pp. 1643–1650, 2009.
- F. Charni, V. Friand, O. Haddad et al., “Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells,” Biochimica et Biophysica Acta, vol. 1790, no. 10, pp. 1314–1326, 2009.
- K. Vuoriluoto, G. Högnäs, P. Meller, K. Lehti, and J. Ivaska, “Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through α2β1 integrin and MT1-MMP,” Matrix Biology, vol. 30, no. 3, pp. 207–217, 2011.
- A. Bouskine, A. Vega, M. Nebout, M. Benahmed, and P. Fénichel, “Expression of embryonic stem cell markers in cultured JKT-1, a cell line derived from a human seminoma,” International Journal of Andrology, vol. 33, no. 1, pp. 54–63, 2010.
- F. Baba, K. Swartz, R. Van Buren et al., “Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype,” Breast Cancer Research and Treatment, vol. 98, no. 1, pp. 91–98, 2006.
- M. E. Lendorf, T. Manon-Jensen, P. Kronqvist, H. A. B. Multhaupt, and J. R. Couchman, “Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma,” Journal of Histochemistry and Cytochemistry, vol. 59, no. 6, pp. 615–629, 2011.
- O. C. Kousidou, A. Berdiaki, D. Kletsas et al., “Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells,” Molecular Oncology, vol. 2, no. 3, pp. 223–232, 2008.
- V. Nikolova, C.-Y. Koo, S. A. Ibrahim et al., “Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression,” Carcinogenesis, vol. 30, no. 3, pp. 397–407, 2009.
- M. Kato, S. Saunders, H. Nguyen, and M. Bernfield, “Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells,” Molecular Biology of the Cell, vol. 6, no. 5, pp. 559–576, 1995.
- S. Leppa, K. Vleminckx, F. Van Roy, and M. Jalkanen, “Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent,” Journal of Cell Science, vol. 109, no. 6, pp. 1393–1403, 1996.
- A. Anttonen, M. Kajanti, P. Heikkilä, M. Jalkanen, and H. Joensuu, “Syndecan-1 expression has prognostic significance in head and neck carcinoma,” British Journal of Cancer, vol. 79, no. 3-4, pp. 558–564, 1999.
- J. P. Wiksten, J. Lundin, S. Nordling, et al., “Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer,” International Journal of Cancer, vol. 95, no. 1, pp. 1–6, 2001.
- M. Fujiya, J. Watari, T. Ashida et al., “Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer,” Japanese Journal of Cancer Research, vol. 92, no. 10, pp. 1074–1081, 2001.
- J. Klatka, “Syndecan-1 expression in laryngeal cancer,” European Archives of Oto-Rhino-Laryngology, vol. 259, no. 3, pp. 115–118, 2002.
- K. Harada, S. Masuda, M. Hirano, and Y. Nakanuma, “Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma,” Human Pathology, vol. 34, no. 9, pp. 857–863, 2003.
- S. Kumar-Singh, W. Jacobs, K. Dhaene, et al., “Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome,” Journal of Pathology, vol. 186, no. 3, pp. 300–305, 1998.
- A. Matsumoto, M. Ono, Y. Fujimoto, R. L. Gallo, M. Bernfield, and Y. Kohgo, “Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential,” International Journal of Cancer, vol. 74, no. 5, pp. 482–491, 1997.
- L. Shah, K. L. Walter, A. C. Borczuk et al., “Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma,” Cancer, vol. 101, no. 7, pp. 1632–1638, 2004.
- A. Woods and J. R. Couchman, “Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component,” Molecular Biology of the Cell, vol. 5, no. 2, pp. 183–192, 1994.
- A. Woods and J. R. Couchman, “Syndecan-4 and focal adhesion function,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 578–583, 2001.
- A. C. Rapraeger, “Syndecan-regulated receptor signaling,” Journal of Cell Biology, vol. 149, no. 5, pp. 995–997, 2000.
- A. Woods, R. L. Longley, S. Tumova, and J. R. Couchman, “Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts,” Archives of Biochemistry and Biophysics, vol. 374, no. 1, pp. 66–72, 2000.
- S. A. Wilcox-Adelman, F. Denhez, and P. F. Goetinck, “Syndecan-4 modulates focal adhesion kinase phosphorylation,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 32970–32977, 2002.
- L. A. Cary, J. F. Chang, and J.-L. Guan, “Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn,” Journal of Cell Science, vol. 109, no. 7, pp. 1787–1794, 1996.
- S. Saoncella, F. Echtermeyer, F. Denhez et al., “Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 2805–2810, 1999.
- S.-T. Lim, R. L. Longley, J. R. Couchman, and A. Woods, “Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase Cα (PKCα) increases focal adhesion localization of PKCα,” Journal of Biological Chemistry, vol. 278, no. 16, pp. 13795–13802, 2003.
- E.-S. Oh, A. Woods, and J. R. Couchman, “Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8133–8136, 1997.
- A. Horowitz, E. Tkachenko, and M. Simons, “Fibroblast growth factor-specific modulation of cellular response by syndecan-4,” Journal of Cell Biology, vol. 157, no. 4, pp. 715–725, 2002.
- G. Chalkiadaki, D. Nikitovic, A. Berdiaki et al., “Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 6, pp. 1323–1331, 2009.
- R. L. Longley, A. Woods, A. Fleetwood, G. J. Cowling, J. T. Gallagher, and J. R. Couchman, “Control of morphology, cytoskeleton and migration by syndecan-4,” Journal of Cell Science, vol. 112, no. 20, pp. 3421–3431, 1999.
- K. S. Midwood, Y. Mao, H. C. Hsia, L. V. Valenick, and J. E. Schwarzbauer, “Modulation of cell-fibronectin matrix interactions during tissue repair,” Journal of Investigative Dermatology Symposium Proceedings, vol. 11, no. 1, pp. 73–78, 2006.
- M. J. Stanley, M. W. Stanley, R. D. Sanderson, and R. Zera, “Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma,” American Journal of Clinical Pathology, vol. 112, no. 3, pp. 377–383, 1999.
- D. Mennerich, A. Vogel, I. Klaman et al., “Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours,” European Journal of Cancer, vol. 40, no. 9, pp. 1373–1382, 2004.
- T. Maeda, C. M. Alexander, and A. Friedl, “Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells,” Cancer Research, vol. 64, no. 2, pp. 612–621, 2004.
- T. Maeda, J. Desouky, and A. Friedl, “Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis,” Oncogene, vol. 25, no. 9, pp. 1408–1412, 2006.